Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Date of Report: February 13, 2026
Event: The Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for bitopertin as a treatment for patients with erythropoietic protoporphyria (EPP).
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Regulatory Status: The FDA issued a CRL for the NDA of bitopertin for EPP, indicating the application was not approved in its current form.
- Documentation: The press release and the CRL are attached as Exhibits 99.1 and 99.2, respectively.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release issued on the same date but does not include the full text of management's outlook or specific next steps within the body of the 8-K.
Risks and Contingencies: The receipt of a CRL represents a significant regulatory risk and a delay in the potential commercialization of bitopertin for EPP. The specific reasons for the CRL and the path to resubmission are detailed in the attached exhibits rather than the summary text of this report.
Investor Verification Checklist
- Review Exhibit 99.2 (Complete Response Letter) to understand the specific deficiencies cited by the FDA.
- Review Exhibit 99.1 (Press Release) for management's immediate response and proposed timeline for addressing the CRL.
- Verify the impact of this regulatory setback on the Company's cash runway and future financing needs, as this filing does not provide updated financial projections.
- Monitor subsequent filings for any updates on the resubmission strategy for the bitopertin NDA.